Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 3

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 3
---
 therefor.

Concurrently and in connection with the execution of the Merger Agreement, Clearwater entered into voting agreements (the “”) with each of (i) FTV IV, L.P., (ii) FTV Investment Holdings, L.P., (iii) ISP V-B EF LP, (iv) ISP V Main Fund EF LLC, (vi) ICONIQ Strategic Partners V, L.P., (vii) ICONIQ
Strategic Partners V-B, L.P., (viii) Oleg Movchan and (ix) CSL Tech Holdings, LLC (each, a “”). Subject to the terms and conditions of each of the Voting
Agreements, each Significant Stockholder has agreed, among other things, to vote all of Enfusion Common Stock, Enfusion Class B Common Stock and Enfusion Common Units held by them (representing in the aggregate approximately 45% of the total
voting power of Enfusion outstanding as of January 7, 2025) in favor of the adoption of the Merger Agreement.

Furthermore,
concurrently and in connection with the execution of the Merger Agreement, Enfusion and certain members of Enfusion OpCo have entered into that certain Amendment No. 1 to the Tax Receivable Agreement (the “”),
pursuant to which such holder of Enfusion Common Units will receive Additional Unit Consideration (as defined in the TRA Amendment) in addition to the Merger Consideration.

The special committee (the “”) of the board of directors of Enfusion (the “”)
unanimously (i) concluded that the terms and conditions of the Merger Agreement, the Mergers and the other transactions contemplated by the Merger Agreement are advisable, fair to and in the best interests of Enfusion and Enfusion Stockholders,
(ii) recommended that the Enfusion Board (a) adopt a resolution (x) adopting and approving (including for purposes of Section 203 of the DGCL), the Merger Agreement, the Mergers and the other transactions contemplated by the
Merger Agreement and (y) declaring that the Merger Agreement, the Mergers and the other transactions contemplated by the Merger Agreement are advisable, fair to and in the best interests of Enfusion and Enfusion Stockholders, and
(b) recommended that the Enfusion Stockholders adopt the Merger Agreement and approve the transactions contemplated by the Merger Agreement,

including the Mergers, (iii) recommended that the Enfusion Board adopt a resolution recommending that the En